Fig. 1

The post-STAMPEDE and CHAARTED data prostate cancer care pathway. The blue boxes represent the localised and locally advanced prostate cancer care pathway in brief. The red boxes represent the advanced prostate cancer care pathway leading to castrate resistance and the therapeutic options at this stage of disease. Steroids such as prednisone are also given as standard care alongside these drugs. The green boxes show docetaxel, now offered upon the initiation of ADT (within 90 days) at newly diagnosed hormone sensitive advanced metastatic disease (M1). This has caused uncertainty in the sequencing of treatments as the disease advances to CRPC as well as the efficacy of these drugs now men have already undergone one docetaxel regimen and are no longer “chemo-naive”. It is also unclear how a second potential docetaxel regimen would be sequenced